BE658392A - - Google Patents
Info
- Publication number
- BE658392A BE658392A BE658392DA BE658392A BE 658392 A BE658392 A BE 658392A BE 658392D A BE658392D A BE 658392DA BE 658392 A BE658392 A BE 658392A
- Authority
- BE
- Belgium
- Prior art keywords
- tetrahydro
- butyl
- naphthyl
- ethanol
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 20
- -1 alpha-butyl Chemical group 0.000 claims 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 13
- 235000019441 ethanol Nutrition 0.000 claims 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 11
- 238000002844 melting Methods 0.000 claims 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 150000001412 amines Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000000047 product Substances 0.000 claims 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 6
- BHRZNVHARXXAHW-UHFFFAOYSA-N Sec-Butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 claims 5
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- 238000009833 condensation Methods 0.000 claims 4
- 230000005494 condensation Effects 0.000 claims 4
- 238000002425 crystallisation Methods 0.000 claims 4
- 230000005712 crystallization Effects 0.000 claims 4
- 238000001640 fractional crystallisation Methods 0.000 claims 4
- 238000005984 hydrogenation reaction Methods 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 4
- 150000003840 hydrochlorides Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000003287 optical Effects 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- XSAYZAUNJMRRIR-UHFFFAOYSA-N 2-acetylnaphthalene Chemical compound C1=CC=CC2=CC(C(=O)C)=CC=C21 XSAYZAUNJMRRIR-UHFFFAOYSA-N 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000000464 adrenergic agent Substances 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 125000006309 butyl amino group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000006073 displacement reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- ZZAIKACKOJSLBZ-UHFFFAOYSA-N 1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanol Chemical compound C1CCCC2=CC(C(O)C)=CC=C21 ZZAIKACKOJSLBZ-UHFFFAOYSA-N 0.000 claims 1
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2H-naphthalen-1-one Chemical compound C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 claims 1
- 206010003119 Arrhythmia Diseases 0.000 claims 1
- 208000004981 Coronary Disease Diseases 0.000 claims 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- 229960004815 Meprobamate Drugs 0.000 claims 1
- 208000003067 Myocardial Ischemia Diseases 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 230000001800 adrenalinergic Effects 0.000 claims 1
- 230000001476 alcoholic Effects 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- XHODMTAOVMFHQJ-UHFFFAOYSA-N aluminum;propan-2-ol Chemical compound [Al].CC(C)O XHODMTAOVMFHQJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 150000003943 catecholamines Chemical class 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 230000002349 favourable Effects 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 231100000053 low toxicity Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 1
- 230000003000 nontoxic Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 229960003147 reserpine Drugs 0.000 claims 1
- 230000001624 sedative Effects 0.000 claims 1
- 231100000486 side effect Toxicity 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/38—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE658392A true BE658392A (de) |
Family
ID=206881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE658392D BE658392A (de) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE658392A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1568289B1 (de) * | 1965-06-11 | 1970-02-19 | Ciba Geigy | 1-Isopropylamino-2-hydroxy-3-(o-methallyloxyphenoxy)-propan,seine applizierbaren Salze und Verfahren zu ihrer Herstellung |
-
0
- BE BE658392D patent/BE658392A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1568289B1 (de) * | 1965-06-11 | 1970-02-19 | Ciba Geigy | 1-Isopropylamino-2-hydroxy-3-(o-methallyloxyphenoxy)-propan,seine applizierbaren Salze und Verfahren zu ihrer Herstellung |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6268533B1 (en) | Formoterol process | |
| US5169868A (en) | Aliphatic propargylamines as specific mao-b inhibitors | |
| EP1753725B1 (de) | Tetrahydroisochinolinsulfonamid-derivate, deren herstellung und therapeutische verwendung | |
| JPH06501262A (ja) | 新規な製法 | |
| EP0003445B1 (de) | 1-Aza-bicyclo(2,2,2)octane, Verfahren zu ihrer Herstellung und Zwischenprodukte, und deren Arzneimittel | |
| FR2546166A1 (fr) | Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique | |
| FR2663328A1 (fr) | Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| EP0004494B1 (de) | 1,3-Dihydro-3-(1-(2-(2,3-dihydro-1,4-benzodioxin-2-yl)2-hydroxy-äthyl)piperidin-4-yl)2H-indol-2-on Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen | |
| CH645090A5 (fr) | Derives de phenylethylamine et leur preparation ainsi que composition contenant ces derives. | |
| FR2625678A1 (fr) | Agents anorexigenes a base de n-(quinuclidin-3-yl)-benzamides ou thiobenzamides | |
| FR2529545A1 (fr) | Nouveaux sels de carnitine ainsi que leur procede de preparation | |
| CA2036337C (fr) | Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant | |
| BE658392A (de) | ||
| FR2643634A1 (fr) | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP0383686A1 (de) | Carboxyalkyl-ether von 2-Amino-7-hydroxytetralin | |
| EP0074903A2 (de) | 2-Amino-1,2,3,4-tetrahydronaphthalen-Derivate, ihre Herstellung und ihre therapeutische Verwendung | |
| EP0173585B1 (de) | Arzneimittel auf Basis von Piperidinderivaten, Piperidinderivate und Verfahren zu ihrer Herstellung | |
| FR2521560A1 (fr) | Nouveaux derives de piperazine et d'homopiperazine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant | |
| US3092660A (en) | 1-acyl-2-alkyl-hydrazine derivatives | |
| EP0244318B1 (de) | N-[(Trimethoxy-2,4,6-benzoyl)-3-propyl]piperidin-Derivate, Verfahren zu ihrer Herstellung und deren Anwendung als Heilmittel | |
| FR2552762A1 (fr) | Nouveaux amides piperaziniques et homopiperaziniques derives de l'acide 3,4-dioxymethylene cinnamique, leur procede de preparation et leur application en therapeutique | |
| FR3067711A1 (fr) | Inhibiteurs de la catechol-o-methyl-transferase (comt) | |
| CA1202631A (fr) | Derives de la quinidine, procede de preparation et application en therapeutique | |
| JPH0341459B2 (de) | ||
| EP0008962B1 (de) | 4-(4-Quinolylpropyl)Piperidinderivate und diese enthaltende Arzneimittel |